DITROPAN XL
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
DITROPAN XL by Johnson & Johnson is clinical pharmacology oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Approved for overactive bladder with symptoms of urge urinary incontinence, urgency, frequency and 2 more indications. First approved in 1998.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DITROPAN XL is an extended-release oral anticholinergic agent containing oxybutynin chloride that treats overactive bladder by relaxing bladder smooth muscle and increasing bladder capacity. It works by inhibiting the muscarinic action of acetylcholine, reducing involuntary detrusor contractions and decreasing urgency and incontinence episodes. The XL formulation provides 24-hour symptom control with stable plasma concentrations, approved for adults and pediatric patients aged 6+ years.
$0.042BPart D
LOE ApproachingAs LOE approaches, the brand team is likely consolidating and shifting focus toward lifecycle management, line extensions, or transition planning, with reduced headcount growth expectations.
Mechanism of Action
CLINICAL PHARMACOLOGY Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to…
Worked on DITROPAN XL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.